New HIV Treatment Approved At GlaxoSmithKline Plc Venture ViiV Healthcare
The shares of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) climbed 1% to 1,680p during early London trade this morning after the pharmaceutical giant confirmed a subsidiary had received FDA approval for a new HIV treatment.
Viiv Healthcare, global experts in specialist HIV treatments, was established as a joint venture between Glaxo and Pfizer in 2009.
The medication, known as Tivicay, is an 'integrase inhibitor' which helps to block the process by which the HIV virus spreads. The product is designed to be used in combination with other anti-retroviral agents in treating HIV-1 in people aged 12 onwards.
ViiV Healthcare chief executive Dr Dominique Limet commented:
"This approval shows that our singular focus on HIV can deliver important new medicines, maintaining our absolute commitment to the HIV/AIDS global response."
With a market cap of over £82bn, GlaxoSmithKline's shares trade at 14.5 times expected earnings, and offer a prospective dividend yield of 4.6%.
But if you already own shares in GlaxoSmithKline and are looking for an alternative growth opportunity, in this exclusive stock research report our top analysts have pinpointed a highly interesting opportunity.
We call it "The Motley Fool's Top Growth Stock For 2013", and it's completely free to download, with no strings attached, available for a limited time only.
Just click here to download it for free!